Influence of opiranserin on quality of recovery in patients undergoing thyroid surgery

Influence of opiranserin on quality of recovery in patients undergoing thyroid surgery: double-blinded randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0011928

Enrollment

134

Registered

2026-05-04

Start date

2026-05-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : 1) The research team will explain the study to individuals meeting the inclusion/exclusion criteria and provide them with sufficient time to consider their participation. Subsequently, upon a f

acetaminophen 1g) as an analgesic and palonosetron 0.075mg for the prevention of postoperative nausea and vomiting (PONV). 5) Subsequently, the pre-prepared study medication will be administered accor

Opiranserin) 1000mg/100mL will be mixed with normal saline to a total volume of 500 mL. The total infusion time will be 10 hours

a loading dose of 80 mL (160mg) will be administered over the first 30 minutes, followed by a maintenance dose of 420 mL (840mg) administered via continuous infusion over the remaining 9 hours and 30

a loading dose of 80 mL will be administered over the first 30 minutes, followed by a maintenance dose of 420 mL administered via continuous infusion over the remaining 9 hours and 30 minutes. 6) Pain

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients (aged 19 years or older) undergoing thyroidectomy

Exclusion criteria

Exclusion criteria: • Patients with a history of hypersensitivity or allergic reactions to the study medication or related compounds • Patients with chronic pain requiring regular analgesic therapy • Patients with cognitive impairment • Pregnant or lactating women, patients lacking decision-making capacity, or patients vulnerable to undue influence regarding voluntary participation • Patients unable to understand the informed consent form (e.g., due to illiteracy, cognitive impairment)

Design outcomes

Primary

Measure	Time frame
postoperative quality of recovery	—

Secondary

Measure	Time frame
postoperative quality of recovery;postoperative depressive mood;total rescue pain killers;postoperative pain score;PONV score	—

Countries

Korea, Republic of

Contacts

Public ContactHyunjik Song

Yonsei University Health System, Gangnam Severance Hospital

anehjsong@gmail.com+82-2-2019-6097

Outcome results